| Author |
Type of study |
Conclusion |
| Harris EE, et al. 2005 [24] |
Retrospective 278 patients |
No clinical impact on cosmesis, complication either modality: No comments on CON V SEQ |
| Azria D, et al. 2005 [25] |
Commentary (retrospective data) |
“Concurrent” increases subcutaneous and pulmonary fibrosis |
| Azria D, et al. 2004 [26] |
Retrospective 147 patients |
“Concomitant”-Tamoxifen (Tam) increases sub-cut breast fibrosis in hypersensitive patients |
| Whelan T, et al. 2005 [27] |
Editorial review |
SEQ or CON: yet to be resolved Randomized trial recommended |
| Pierce LJ, et al. 2005 [28] |
Prospective randomized, 309 pts |
No difference in adverse effect, local or systemic recurrence RT + TAM or RT only |
| Ismail SS, et al. 2013 [29] |
Prospective 160 patients |
No difference RT + CON or SEQ |
| Bentzen SM, et al. 1996 [30] |
Retrospective 84 patients |
Increase in lung fibrosis in CON Group |
| Ishitobi M, et al. 2009 [31] |
Retrospective 264 patients |
No difference between CON and SEQ Group |
| Tsoutsou PG, et al. 2010 [32] |
Review |
May be given CON or SEQ (RT) Combination of Tamoxifen and Letrozole recommended |
| Ahn PH, et al. 2005 [33] |
Retrospective 495 patients |
CON did not affect local control No observation on cosmesis and toxicity |
| Koc M, et al. 2002 [34] |
Prospective 111 patients |
RT + TAM V RT + 0: Tele cobalt RT Significant risk of lung fibrosis. No comment on CON V SEQ |
| Cecchini MJ, et al. 2015 [35] |
Literature review |
SEQ supported due to increase in lung fibrosis in CON treatment |
| Munshi A, et al. 2011 [36] |
Randomized prospective |
Results awaited (major study) |